The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | Sequencing of therapies to improve outcomes of CLL patients
Martina Seiffert, PhD, German Cancer Research Center, Heidelberg, Germany, discusses the necessity of sequencing and combining therapies rationally in patients with chronic lymphocytic leukemia (CLL) to ensure T-cell activation, in order to improve outcomes of patients receiving immune checkpoint or CAR T-cell therapies. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
